Filing summary
Entity and period: The supplied filing is ARCA biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed February 27, 2019. It is not an Oruka Therapeutics filing, and it reports a full fiscal year rather than a standalone 2018 fourth quarter.
Business context
ARCA was a clinical-stage biopharmaceutical company developing genetically targeted cardiovascular therapies. Its lead candidate, Gencaro (bucindolol), was investigational and aimed at preventing recurrent atrial fibrillation in selected heart-failure patients. The company also began IND-enabling work on AB171 for potential heart-failure and peripheral arterial disease indications. ARCA reported no product revenue.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $4.239 million | $14.076 million |
| General and administrative expense | $3.879 million | $4.636 million |
| Net loss | $7.933 million | $18.490 million |
| Cash used in operating activities | $8.244 million | $17.472 million |
| Cash, cash equivalents and marketable securities at year-end | $6.608 million | $11.752 million |
| Total liabilities | $0.793 million | $2.090 million |
Lower R&D spending primarily reflected completion of the GENETIC-AF trial and reduced clinical-material production. The company had no debt outstanding at December 31, 2018. Its total stockholders’ equity was $6.032 million, down from $10.275 million. Profitability and operating margins are not meaningful for this pre-commercial company with no revenue.
Net cash from financing activities was $3.104 million in 2018, mainly from common-stock sales, partly offset by vendor-financing repayments. After year-end, ARCA raised approximately $2.4 million in net proceeds through its at-the-market equity program. Management said the year-end cash plus those proceeds were expected to fund operations at the projected cost structure through the third quarter of 2019. The auditor and management nevertheless identified substantial doubt about the company’s ability to continue as a going concern.
Material developments and outlook
- In the 267-patient Phase 2B GENETIC-AF trial, Gencaro showed a similar treatment effect to metoprolol in the overall population. Favorable statistically significant findings cited for selected analyses included the HFmrEF subgroup (N=91; HR 0.42; p=0.017) and a prespecified-analysis population described by the company (N=196; HR 0.54; p=0.011). These subgroup findings do not change the overall-trial result.
- In February 2019, the FDA agreed to a Special Protocol Assessment for the proposed PRECISION-AF Phase 3 trial. The planned adaptive, active-controlled study was expected to enroll about 400 genotype-selected HFmrEF patients. ARCA anticipated a fourth-quarter 2019 start, conditional on obtaining significant additional financing. An SPA does not guarantee trial success or FDA approval.
- Management expected 2019 R&D expense to exceed 2018 if PRECISION-AF began, and to be lower if it did not. G&A expense was expected to be broadly consistent with 2018.
- ARCA had used all shares available under its current prospectus by February 22, 2019; further funding needs could require additional equity, debt, or a strategic transaction, with potential dilution or financing constraints. Failure to secure funding could lead to delayed or discontinued development or operations.
- Nasdaq had granted an extension through April 8, 2019 to regain the $1.00 minimum bid-price requirement. Stockholders had authorized a possible reverse split, but the board had not selected a ratio.
- AB171 remained in preclinical development, with further work dependent on available capital. The filing also describes potential Gencaro milestone and royalty obligations upon approval and commercialization; ARCA stated that an earlier transaction reduced or could eliminate some obligations.
Important investor verification points
- Confirm the issuer and filing identity: the document is for ARCA biopharma, Inc. (ticker ABIO), not Oruka Therapeutics.
- Review the subsequent financing, remaining funding capacity, cash runway, and any later going-concern disclosures.
- Check whether PRECISION-AF was funded and initiated, and assess the trial design, enrollment, endpoints, results, and any subsequent FDA actions.
- Assess Nasdaq listing compliance, any reverse split, and the dilution and availability of future financing.
- Verify the status and potential amounts of Gencaro licensing milestones and royalties, and the progress and funding requirements for AB171.